Related references
Note: Only part of the references are listed.Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Laura L. Meijer et al.
ANNALS OF SURGERY (2020)
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Albrecht Neesse et al.
GUT (2019)
Confirmation practice in pharmacogenetic testing; how good is good enough?
Carin A. T. C. Lunenburg et al.
CLINICA CHIMICA ACTA (2019)
Molecular subtypes of pancreatic cancer
Eric A. Collisson et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/ Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer
Lesley Seymour et al.
CLINICAL LUNG CANCER (2019)
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments
S. Tavolari et al.
EUROPEAN JOURNAL OF CANCER (2019)
Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma
Cindy Neuzillet et al.
JOURNAL OF PATHOLOGY (2019)
The evidence framework for precision cancer medicine
Jeffrey A. Moscow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy
Vachiranee Limviphuvadh et al.
BMC CANCER (2018)
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
N. O. Elander et al.
BRITISH JOURNAL OF CANCER (2018)
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma
Natalie Cook et al.
BRITISH JOURNAL OF CANCER (2018)
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma
Akihisa Kato et al.
HUMAN PATHOLOGY (2018)
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Therapeutic developments in pancreatic cancer: current and future perspectives
John P. Neoptolemos et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
5'-nucleotidase cN-II emerges as a new predictive biomarker of response to gemcitabine/platinum combination chemotherapy in non-small cell lung cancer
Francesca Toffalorio et al.
Oncotarget (2018)
Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer
Tomohiro Kondo et al.
Oncotarget (2018)
How to overcome ATP-binding cassette drug efflux transporter-mediated drug resistance?
Adrian C. Jaramillo et al.
CANCER DRUG RESISTANCE (2018)
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX
Amikar Sehdev et al.
CLINICAL CANCER RESEARCH (2018)
Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
Eileen Mary O'Reilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) plus capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2).
Herbert Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer
E. Giovannetti et al.
SEMINARS IN CANCER BIOLOGY (2017)
Pancreas adenocarcinoma: novel therapeutics
Benjamin A. Krantz et al.
CHINESE CLINICAL ONCOLOGY (2017)
Going the Extra Mile Improved Survival for Pancreatic Cancer Patients Traveling to High-volume Centers
Michael E. Lidsky et al.
ANNALS OF SURGERY (2017)
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Cristoforo Grasso et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic review
Denis L. Jardim et al.
CANCER TREATMENT REVIEWS (2017)
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
Joseph Ciccolini et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Lucy Ireland et al.
CANCER RESEARCH (2016)
On the pharmacogenetics of non-small cell lung cancer treatment
Mariacarmela Santarpia et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Bioinformatic analysis reveals pancreatic cancer molecular subtypes specific to the tumor and the microenvironment
Tessa Y. S. Le Large et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Intra-tumour heterogeneity - going beyond genetics
Francisco Caiado et al.
FEBS JOURNAL (2016)
Genetics and biology of pancreatic ductal adenocarcinoma
Haoqiang Ying et al.
GENES & DEVELOPMENT (2016)
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts
Harrison Kim et al.
MOLECULAR CANCER THERAPEUTICS (2016)
A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns
Faiyaz Notta et al.
NATURE (2016)
Limits to Personalized Cancer Medicine
Ian F. Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
Chiara Caparello et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation
Mark Borris D. Aldonza et al.
ONCOTARGET (2016)
Pancreatic cancer
Jorg Kleeff et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Evaluation of Pancreatic Cancer Clinical Trials and Benchmarks for Clinically Meaningful Future Trials A Systematic Review
Lola Rahib et al.
JAMA ONCOLOGY (2016)
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
Jean-Baptiste Bachet et al.
BMC CANCER (2015)
Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival (vol 25, pg 719, 2014)
Berna C. Oezdemir et al.
CANCER CELL (2015)
Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
Wan-Ching Yen et al.
CLINICAL CANCER RESEARCH (2015)
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2015)
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial
M. Sinn et al.
EUROPEAN JOURNAL OF CANCER (2015)
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Albrecht Neesse et al.
GUT (2015)
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I. Hurwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Ignacio Garrido-Laguna et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas
Mie Grunnet et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
Michela Capello et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma
D. Propper et al.
ANNALS OF ONCOLOGY (2014)
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia
M. Maftouh et al.
BRITISH JOURNAL OF CANCER (2014)
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
E. Van Cutsem et al.
BRITISH JOURNAL OF CANCER (2014)
Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
Andrew D. Rhim et al.
CANCER CELL (2014)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
Pharmacogenetics in the Cancer Clinic: From Candidate Gene Studies to Next-Generation Sequencing
H-J Guchelaar et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
On the use of pharmacogenetics in cancer treatment and clinical trials
Jacques Robert et al.
EUROPEAN JOURNAL OF CANCER (2014)
Gemcitabine: Metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
Lucas de Sousa Cavalcante et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
SPARC independent drug delivery and antitumour effects of nab-paclitaxel in genetically engineered mice
Albrecht Neesse et al.
GUT (2014)
Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
William Greenhalf et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis
Sandra S. McAllister et al.
NATURE CELL BIOLOGY (2014)
Recent studies of 5-fluorouracil resistance in pancreatic cancer
Wei-Bin Wang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
Jun-Eul Hwang et al.
BMC CANCER (2013)
Stromal expression of SPARC in pancreatic adenocarcinoma
Cindy Neuzillet et al.
CANCER AND METASTASIS REVIEWS (2013)
Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
Amir Avan et al.
CANCER RESEARCH (2013)
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back
Amir Avan et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
Elizabeth Poplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
Albrecht Neesse et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Pancreatic cancer: why is it so hard to treat?
Paul E. Oberstein et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2013)
The Impact of the Activated Stroma on Pancreatic Ductal Adenocarcinoma Biology and Therapy Resistance
Mert Erkan et al.
CURRENT MOLECULAR MEDICINE (2012)
Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
Maha Elnaggar et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells
Fu Li et al.
FEBS JOURNAL (2012)
Origin of pancreatic ductal adenocarcinoma from atypical flat lesions: a comparative study in transgenic mice and human tissues
Michaela Aichler et al.
JOURNAL OF PATHOLOGY (2012)
Direct histological processing of EUS biopsies enables rapid molecular biomarker analysis for interventional pancreatic cancer trials
Rebecca J. Brais et al.
PANCREATOLOGY (2012)
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Chen Sun et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
nab-Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
Kristopher K. Frese et al.
CANCER DISCOVERY (2012)
Three Cheers for Targeted Therapy in Non-Small Cell Lung Cancer ... When We Hit The Target!
G. Codacci-Pisanelli et al.
JOURNAL OF CHEMOTHERAPY (2011)
Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Integrating pharmacogenetics into gemcitabine dosing-time for a change?
Joseph Ciccolini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity
S. Leskelae et al.
PHARMACOGENOMICS JOURNAL (2011)
Pharmacogenomics of paclitaxel
Cristina Rodriguez-Antona
PHARMACOGENOMICS (2010)
Irinotecan pharmacogenomics
Sharon Marsh et al.
PHARMACOGENOMICS (2010)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
Volker Heinemann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine
E Giovannetti et al.
CANCER RESEARCH (2006)
Effect of gemcitabine on the expression of a poptosis-related genes in human pancreatic cancer cells
Pei-Hong Jiang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona et al.
ONCOGENE (2006)
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel
N Desai et al.
CLINICAL CANCER RESEARCH (2006)
Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel
P Sève et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy
DM Kweekel et al.
CANCER TREATMENT REVIEWS (2005)
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis
B Schniewind et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Clinical significance of dihydropyrimidine dehydrogenase in adjuvant 5-fluorouracil liver perfusion chemotherapy for pancreatic cancer
S Nakayama et al.
ANNALS OF SURGERY (2004)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
5-Fluorouracil: Mechanisms of action and clinical strategies
DB Longley et al.
NATURE REVIEWS CANCER (2003)
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents
ZW Xu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2002)
Hospital volume and surgical mortality in the United States.
JD Birkmeyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
